Skip to main content

Table 3 Summary of concentration-QTc analysis

From: The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects

Study treatment

Geometric mean Cmax

(90% CI) (μg/mL)

ΔΔQTcF Estimate

(90% CI) (ms)

Concentration-QTc slope

(90% CI) (ms per μg/mL)

Treatment effect-specific intercept

(90% CI) (ms)

Lucerastat

1000 mg

5.2 (4.96, 5.55)

0.39 (− 0.13, 0.90)

0.07 (0.01, 0.13)

p = 0.0618

0.03 (− 0.51, 0.57)

p = 0.9307

4000 mg

24. 3 (23.05, 25.68)

1.69 (0.33, 3.05)

Moxifloxacin

400 mg

3.0 (2.78, 3.25)

16.35 (14.03, 18.68)

4.47 (3.58, 5.36)

p < 0.0001

2.89 (1.82, 3.97)

p < 0.0001

  1. CI, confidence interval; Cmax, maximum plasma concentration; Δ, change-from-baseline; ΔΔ, placebo-corrected change-from-baseline; QTcF, Fridericia-corrected QTc